Human vWF-A2 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF2764
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Asp1498-Val1665
Accession # NP_000543
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human vWF-A2 Antibody
Detection of Human vWF‑A2 by Western Blot.
Western blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human vWF-A2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2764) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). Specific bands were detected for vWF at approximately 250 kDa and the vWF precursor at 360-460 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Detection of Human vWF-A2 by Simple WesternTM.
Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells, loaded at 0.2 mg/mL. A specific band was detected for vWF-A2 at approximately 250-350 kDa (as indicated) using 5 µg/mL of Sheep Anti-Human vWF-A2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2764) . This experiment was conducted under reducing conditions and using the 66-440 kDa separation system.Applications for Human vWF-A2 Antibody
Immunoprecipitation
Sample: Conditioned cell culture medium spiked with Recombinant Human vWF-A2 (Catalog # 2764‑WF), see our available Western blot detection antibodies
Simple Western
Sample: HUVEC human umbilical vein endothelial cells
Western Blot
Sample: HUVEC human umbilical vein endothelial cells
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: vWF-A2
von Willebrand Factor (vWF) is a large, multimeric glycoprotein made by endothelial cells and megakaryocytes. The pre-pro-vWF protein contains 2813 amino acids (aa), which consists of 22 aa signal peptide, 741 aa propeptide and mature vWF monomer of 2050 aa (1‑4). The pro-vWF undergoes dimerization in the endoplasmic reticulum (ER) through C-terminal “cysteine-knot” (CK) domain. The pro-vWF dimmers are transported to Golgi and form multimers by forming disulfide bond in amino‑terminal region of the mature form. The proteolytic processing of pro-region also occurs in Golgi. The matured vWF is stored in Weibel-Pallade bodies in endothelial cells and granules in megakaryocytes and platelets. The unusually-large vWF (ulvWF) multimers released from cells are very efficient in binding to platelets to form thrombus. The population of these highly active ulvWF multimers is controlled by a specific protease, ADAMTS13, which cleaves between residues Tyr1605 and Met1606 in the A2 domain of vWF. In the plasma, vWF appears as a series of large and intermediate multimers with molecular masses from several thousand to 500 kDa. vWF also performs hemostatic functions (3‑5). In a high shear-stressed environment, vWF undergoes conformational change to expose a binding site for glycoprotein Ib alpha. As a result, vWF facilitates aggregation of platelets. In addition to platelet binding, vWF binds coagulation factor VIII to increase the lifetime of FVIII in plasma. The purified rhvWF-A2 contains the A2 domain of vWF.
References
- Sadler, J. E. (1998) Annu. Rev. Biochem. 67:395.
- Ruggeri, Z. M. (2003) Cur. Opin. Hemat. 10:142.
- Michiels, J. J. et al. (2006) Clin. Appl. Thromb. Hemost. 12:397.
- Groot, E. et al. (2007) Cur. Opin. Hemat. 14:284.
- Lenting, P. J. et al. (2007) J. Thromb. Haemos. 5:1353.
Long Name
Alternate Names
Gene Symbol
Additional vWF-A2 Products
Product Documents for Human vWF-A2 Antibody
Product Specific Notices for Human vWF-A2 Antibody
For research use only